Table 3.
List of quality indicators (QI) and scores
| Cancer types | Target patients | Specified care | Number of patients (N) | Proportion of patients receiving specified care (% [95% confidence interval]) |
|---|---|---|---|---|
| Stomach | ||||
| QI 1 | pStage II or III (excluding pT1, pT3N0) gastric cancer patients who were discharged within 6 weeks of receiving curative surgery | Patients who received S‐1 adjuvant chemotherapy within 8 weeks of surgery | 2258 | 62.8 [60.8, 64.8] |
| Colorectal | ||||
| QI 2 | pStage III colorectal cancer patients who received curative surgery | Patients who received one of the following adjuvant chemotherapy within 8 weeks of surgery: 5FU + LV, UFT + LV, FOLFOX, Cape, CapeOX† | 5127 | 44.8 [43.4, 46.2] |
| Lung | ||||
| QI 3 | Stage I–II non‐small cell lung cancer patients | Patients who received resection surgery or stereotactic body radiotherapy | 10 026 | 85.4 [84.7, 86.1] |
| QI 4 | pStage II–IIIA non‐small cell lung cancer patients who received curative surgery | Patients who received adjuvant platinum‐based chemotherapy within 6 months of surgery | 1691 | 49.0 [46.6, 51.4] |
| Breast | ||||
| QI 5 | Breast cancer patients under the age of 70, who received breast‐conserving surgery | Patients who received postoperative radiation within 20 weeks of surgery | 8258 | 73.6 [72.7, 74.6] |
| QI 6 | Patients with invasive breast cancer | Patients tested for HER2‡ | 16 332 | 83.3 [82.7, 83.8] |
| QI 7 | pT3–4 and not pN0, or pN2‐3 breast cancer patients | Patients who received postoperative radiation within 20 weeks | 966 | 26.5 [23.7, 29.4] |
| Liver | ||||
| QI 8 | Liver cancer patients who underwent liver resection surgery for the first time | Patients who received indocyanine green testing prior to the date of surgery | 2094 | 91.4 [90.1, 92.6] |
| Prostate | ||||
| QI 9 | pT3N0M0 prostate cancer patients who received surgical resection | Patients who received postoperative radiation or hormone therapy within a year of surgery | 772 | 19.6 [16.8, 22.5] |
| QI 10 | Locally advanced prostate cancer patients (cT3‐4cN1‐3 and M0) | Patients receiving combined androgen blockade therapy | 1973 | 80.9 [79.1, 82.7] |
| Cervical | ||||
| QI 11 | Cervical cancer patients clinically staged cT1‐2, but pathologically pN1‐3, M0 | Patients who received postoperative chemoradiation within 6 months | 197 | 37.1 [30.3, 44.2] |
| All (Supportive care) | ||||
| QI 12 | Patient who received highly‐emetic chemotherapy | Patients who received prophylaxtic anti‐emetics with aprepitant (NK1 antagonist§), serotonin antagonist (5HT3 antagonist¶), and corticosteroids at the same time as chemotherapy treatment | 10 104 | 68.1 [67.2, 69.0] |
| QI 13 | Patients who were started on narcotics in an outpatient settings for the first time | Patients who received laxatives to prevent constipation before or at the same time a narcotic is started | 2610 | 64.9 [63.1, 66.8] |
†Cape, capecitabine; CapeOX, capecitabine and oxaliplatin; FOLFOX, 5‐fluorouracil, leucovorin and oxaliplatin; 5FU + LV, 5‐fluorouracil and leucovorin; UFT + LV, uracil/ftorafur and leucovorin; ‡HER2: human epidermal growth receptor; §NK1, neurokinin 1; ¶5HT3: 5‐hydroxytryptamine.